Michael Kauffman
CIK 1364719 · President of Development · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$824.9K
Companies
11
Total Filings
117
Lifetime Open-Market Net
-$20.02M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYNB | Director | — | $6.97 | — | $0 | 1 | 2026-06-17 |
| Kezar Life Sciences, Inc. (KZR) Delisted | Director | 0 | $7.29 | $0 | -$82.2K | 11 | 2026-05-11 |
| VSTM | President of Development | 8,666 | $6.23 | $54.0K | -$51.8K | 19 | 2026-01-08 |
| KYNTRA BIO, INC. (FGEN) Delisted | Director | — | $9.75 | — | $0 | 1 | 2025-06-06 |
| NCNA | Director | — | $1.29 | — | $0 | 1 | 2024-08-23 |
| ACET | Director | 738 | $8.20 | $6.1K | -$8.4K | 5 | 2024-06-07 |
| KPTI | Chief Executive Officer | 107,874 | $7.09 | $764.8K | -$19.88M | 64 | 2022-03-02 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | — | $0.04 | — | $0 | 3 | 2019-06-14 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Chief Medical Officer | 9,000 | — | — | $0 | 2 | 2010-02-11 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Director | — | — | — | $0 | 3 | 2010-01-20 |
| BIOENVISION INC (BIVN) Delisted | Director | — | — | — | $0 | 1 | 2007-01-05 |
Recent Filings · Page 2 of 12
117 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-20 | VSTM | Grant (A) | +8,333 | $0 | EDGAR |
| 2024-06-07 | ACET | Mixed | — | -$8.4K | EDGAR |
| 2024-06-05 | ACET | Notice (144) | −5,900 | -$8.4K | EDGAR |
| 2024-03-13 | VSTM | Mixed | — | $0 | EDGAR |
| 2023-08-16 | ACET | Mixed | — | $0 | EDGAR |
| 2023-07-26 | Kezar Life Sciences, Inc. (KZR) Delisted | Mixed | — | $0 | EDGAR |
| 2023-06-16 | Kezar Life Sciences, Inc. (KZR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | ACET | Grant (A) | +5,900 | $0 | EDGAR |
| 2023-05-16 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2022-12-20 | VSTM | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.